IF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL 604-875-4077 IMMEDIATELY



VA: VGH / UBCH / GFS VC: BP / Purdy / GPC

ORDERS

ADDRESSOGRAPH

| COMPLETE OR REVIEW ALLERGY STA | TUS PRIOR TO WRITING ORDERS | | | | | |
|--|--|---|--|--|--|--|
| BMT RIC BU2FLUATG | | | | | | |
| MISMATCHED UNRELATED OR MISMATCHED RELATED DONOR ALLOGENEIC STEM CELL TRANSPLANT REDUCED INTENSITY CONDITIONING with BUSULFAN, FLUDARABINE and ANTI-THYMOCYTE GLOBULIN | | | | | | |
| (items with check boxes must be | | (Page 1 of 4) | | | | |
| Date: Time: | | Time Processed RN/LPN Initials Comments | | | | |
| Consent signed for chemotherapy | | | | | | |
| Must be completed prior to ordering chemotherapy: This woman of child bearing potential has been assessed for the possibility of pregnancy. | | | | | | |
| Prescriber signature Printed name | College ID | | | | | |
| Chemotherapy Dosing Calcul | ations | | | | | |
| Height: cm | Actual Weight: kg | | | | | |
| Document height and weight on Nursing Assessment Form | and must be co-signed by 2 RNs | | | | | |
| $BMI(kg/m^{2}) = \frac{Weight(kg)}{[Height(m)]^{2}}$ | BMI = kg/ m² | | | | | |
| https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi-m.htm | | | | | | |
| Ideal Body Weight: Male = 50 + 0.91 (height in cm – 152.4) | Ideal Body Weight = kg | | | | | |
| Female = 45.5 + 0.91 (height in cm – 152.4) Adjusted Body Weight (ABW): | | | | | | |
| ABW = Ideal Body Weight (IBW)+ 0.4(Actual Body Weight – IBW) | Adjusted Body Weight = kg | | | | | |
| $BSA(m^2) = \sqrt{\frac{Height(cm) \times Weight(kg)}{3600}}$ | BSA = m² | | | | | |
| Round all BSA calculations to 2 decimal places | Adjusted BSA = m² | | | | | |
| Use Adjusted body weight or Adjusted BSA to calculate chemotherapy dos Weight | es when Ideal Body Weight is less than Actual | | | | | |
| MONITORING: | | | | | | |
| During each anti-thymocyte globulin (rabbit) infusion: Monitor vital signs | s Q15MIN x 4; then Q30MIN x 4; then Q4H | | | | | |
| LABORATORY: | | | | | | |
| Day +2 (date): draw cycloSPORINE level and repeat eve | ry Monday and Thursday. | | | | | |
| Day +1 (date):, day+3 (date):, day +6 (date):dra methotrexate dosing. | w serum creatinine and bilirubin level in AM for | | | | | |
| Day +7 (date):draw CMV PCR then repeat every Monda | y through day +100 or longer if indicated. | | | | | |
| Day +7 (date):draw EBV PCR then repeat every Monday through day+100 or longer if indicated. | | | | | | |
| | | | | | | |
| Dragorihor's Cignoture | Callaga ID | | | | | |
| Prescriber's Signature Printed Name BMT10-02 VCH.VA.PPO.751 Rev.J | College ID UL.2022 | | | | | |

IF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL 604-875-4077 IMMEDIATELY



VC: BP / Purdy / GPC

ORDERS

ADDRESSOGRAPH

COMPLETE OR REVIEW ALLERGY STATUS PRIOR TO WRITING ORDERS

BMT RIC BU2FLUATG

MISMATCHED UNRELATED OR MISMATCHED RELATED DONOR ALLOGENEIC STEM CELL TRANSPLANT

| REDUCED INTENSITY CONDITIONING with BUSULFAN, FLUDARABINE and ANTI-THYMOCYTE GLOBULIN (items with check boxes must be selected to be ordered) (Page 2 of 4) | | | |
|---|---|--|--|
| Date: Time: | Time Processed RN/LPN Initials Comments | | |
| CHEMOTHERAPY: BCCA Code for PCIS order entry: BMTNOS | | | |
| All intensive chemotherapy and transplant chemotherapy orders require 2 prescriber signatures, one of whom must be an attending physician. | | | |
| fludarabinemg (30 mg/m², round to nearest 5 mg) in dextrose 5% (D5W) IV daily over 30 minutes at 09:00. Adjust dose when CrCl is 70 mL/min or less. Refer to Notes to Prescriber. | | | |
| Start day -8 (date) to day -4 (date) Total of 5 doses. | | | |
| LORazepam 1 mg PO/SL/IV Q6H (at 09:00, 15:00, 21:00, 03:00) for seizure prophylaxis. Start at 09:00. | | | |
| Start day –5 (date):to day -3 (date): | | | |
| busulfanmg (3.2 mg/kg, round to nearest 5 mg) in sodium chloride 0.9% (NS) IV daily over 3 hours at 10:00. | | | |
| Start day -5 (date):to day -4 (date): Total of 2 doses. | | | |
| antithymocyte globulin rabbit (THYMOGLOBULIN) mg (1.5 mg/kg, actual body weight, round to nearest 5 mg) IV daily at 09:00. | | | |
| Start day –3 (date):to day -1 (date): Total of 3 doses | | | |
| Premedications for each antithymocyte globulin rabbit infusion: diphenhydrAMINE 50 mg PO x 1 dose one hour prior to, and Q4H during the infusion acetaminophen 650 mg PO x 1 dose one hour prior to, and Q4H during the infusion hydrocortisone 100 mg IV x 1 dose one hour prior | | | |
| Infuse antithymocyte globulin rabbit through an in-line 0.2 micron filter. Initial dose (day -3) to be infused over 8 to 12 hours (up to 24 hours). If no reaction, subsequent doses can be infused over a minimum of 4 hours. Confirm with Pharmacy before each dose . | | | |
| Hematopoietic progenitor cells to be infused on day 0 (date): | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Prescriber's Signature Printed Name College ID BMT10-02 VCH.VA.PPO.751 Rev.JUL.2022 | | | |

IF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL 604-875-4077 IMMEDIATELY



VA: VGH / UBCH / GFS VC: BP / Purdy / GPC

ORDERS

ADDRESSOGRAPH

COMPLETE OR REVIEW ALLERGY STATUS PRIOR TO WRITING ORDERS

BMT RIC BU2FLUATG

| MISMATCHED UNRELATED OR MISMATCHED RELATED DONOR ALLOGENEIC STEM CELL TRANSPLANT REDUCED INTENSITY CONDITIONING with BUSULFAN, FLUDARABINE and ANTI-THYMOCYTE GLOBULIN | | |
|--|--|---|
| (ite | ms with check boxes must be selected to be ordered) | (Page 3 of 4) |
| Date: | Time: | Time Processed RN/LPN Initials Comments |
| Graft versus Host Disease Prophylo BCCA Code for PCIS order entry: NC | | |
| | mg (1.5 mg/kg, use actual weight, round dose to nearest 5 mg) in dextrose 5% d 18:00. Infuse over 4 hours. Start at 18:00 on day -2 (date) | |
| methotrexate mg (5 | mg/m², round to nearest 1 mg) IV over 20 minutes on the following dates: | |
| | day +3 (date): t 24 hours after hematopoietic progenitor infusion. o each dose. | |
| SUPPORTIVE CARE: | | |
| ursodiol (choose ONE dosing reg 250 mg PO BID (for we 250 mg PO Q0800 and 500 mg PO BID (for we | ight less than 40 kg) 500 mg PO Q2000 (for weight 40 kg to 70 kg) | |
| Start day –10 (date): | and continue until day +90 (date): | |
| allopurinol 300 mg PO daily x 10 infusion. Start on day -9 (| days for all patients not in remission at time of hematopoietic progenitor cell date): | |
| If HSV seropositive recipient give valACYclovir 500 mg | e: PO BID. Start day +1 (date): | |
| Antiemetics: as per completed ANTI | EMETIC REGIMEN-LEUKEMIA/BMT (#412) PRE-PRINTED orders. | |
| Fever orders: as per completed INIT PRE-PRINTED Orders. | AL FEBRILE NEUTROPENIA OR INFECTION MANAGEMENT- INPATIENT (#302) | |
| Cell Infusion: as per completed INFU (#503) PRE-PRINTED Orders. | ISION of HEMATOPOIETIC PROGENITOR CELLS or THERAPEUTIC CELLS | |
| | | |
| Prescriber's Signature BMT10-02 | Printed Name College ID VCH.VA.PPO.751 Rev.JUL.2022 | |

IF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL 604-875-4077 IMMEDIATELY Vancouver CoastalHealth

VA: VGH / UBCH / GFS VC: BP / Purdy / GPC

ORDERS

ADDRESSOGRAPH

COMPLETE OR REVIEW ALLERGY STATUS PRIOR TO WRITING ORDERS

| BMT RIC BU2FLUATG MISMATCHED UNRELATED OR MISMATCHED RELATED DONOR ALLOGENEIC STEM CELL TRANSPLANT REDUCED INTENSITY CONDITIONING with BUSULFAN, FLUDARABINE and ANTI-THYMOCYTE GLOBULIN | | | | |
|---|--|--|---|--|
| | (items with check boxes must be selected to be ordered) | | (Page 4 of 4) | |
| Date: | Time: | | Time Processed RN/LPN Initials Comments | |
| NO | TES TO PRESCRIBER (Unit Clerk/Pharmacy do not process – reminders for Prescriber only). | | | |
| | If CrCl is 70 mL/min or lower, decrease fludarabine dose by 20%. Reassess need for dose adjustment daily. | | | |
| | If HBsAg or Anti-HBc positive start lamivudine 100 mg PO daily (complete Special Authority Form) and continue for at least 12 months post-transplant or longer if patient continues immunosuppressive drugs. | | | |
| | PJP prophylaxis should be started by day +28 and continue until at least 12 months post transplant or longer if patient continues immunosuppressive drugs. | | | |
| | Continue VZV prophylaxis until at least 12 months post transplant or longer if patient continues immunosuppressive drugs. | | | |
| | Refer to L/BMT manual for methotrexate dosing guidelines. | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | criber's Signature Printed Name College ID '10-02 VCH.VA.PPO.751 Rev.JUL.2022 | | | |